| Literature DB >> 32214925 |
Brian M Polster1, Rafael Arze2, Matthew H Lyttle2, David G Nicholls1, Derek Hudson2.
Abstract
A step-by-step evaluation of dual-labeled FRET substrates for the protease calpain is reported. The study led to cell permeable selections, with optimized specificity and effectiveness for the target enzyme, and improved stability to non-specific degrading enzymes. © Springer Science+Business Media, Inc. 2006.Entities:
Keywords: Black Hole Quencher; CAL Fluor dye; FRET protease assay; calpain substrates; cell-based assay(s); solid phase peptide synthesis
Year: 2006 PMID: 32214925 PMCID: PMC7088158 DOI: 10.1007/s10989-006-9049-9
Source DB: PubMed Journal: Int J Pept Res Ther ISSN: 1573-3149 Impact factor: 1.931
Preliminary screening of substrate sequences for calpain assay development
| Code | Sequence | Calpain | Trypsin (T), α-Chymotrypsin (C) | S-N/N Pronase E | Sequence source |
|---|---|---|---|---|---|
| cA | GSGTSS | + | T −, C − | 450 | Vimentin, Fischer et al., |
| cB | TPLKSPPPPSPR | + | T ++, C − | 250 | Tompa et al., |
| cG | EVYGM*M* | + | T −, C ++ | 1600 (P) 650 ( | α-Spectrin, Mittoo et al., |
| cJ | VVTAEA | + | T −, C − | 320 | MAP2c, Friedrich, P. et al., unpublished |
| cM§ | VVQAGI | + | T −, C − | 520 (P) 300 ( | CaM-PDE1A2, Kakkar et al., |
| cW | PLFAER | ++ | T ++, C ++ | 650 | Cuerrier et al., |
Substrate sequences, except as noted in footnotes, bear at the N-terminus the standard CFO-1 fluorophore and Lys(BHQ-2)-amide at the C-terminus.
+ Designates poor substrate, ++ good substrate, − stable or very slowly cleaved.
‡ Note Tompa et al. describe DABCYL-TPLKSPPPSPR-EDANS but the cited Exptl. describes synthesis of DABCYL-TPLK(EDANS)SPPPSPR. cB was prepared in both forms, the latter a poor substrate for any test enzyme.
* Prepared with isosteric more stable norleucine rather than the published methionine residues.
P, C – extension = PEG; aR, C extension = d-Ala-Arg; † Dye form Ac-Lys(CFO-u1), C extension = d-Ala-Arg.
§ Poorly soluble in standard form, prepared with d-Ala-Arg, and PEG tail.
Optimization of peptide cW
| Code | Substrate | CFO variant | S-N/N Pronase E | Trypsin, Chymotrypsin |
|---|---|---|---|---|
| cW | PLFAER | CFO-1 | 650 | T ++, C ++ |
| cX | PLFAERP | CFO-1 | 651 | T+, C++ |
| cXa | PLGAERP | CFO-1 | 797 | T +, C+ |
| cXb | PLLAERP | CFO-1 | 867 | T+, C++ |
| cXc | PLVAERP | CFO-1 | 1162 | T+, C+ |
| cXe | PLLAERP | CFO-3 | 1156 | T+, C+ |
| cXf | PLLAERP | Ac-K(CFO-1) | 1392 | T+, C+ |
| cXg | PLLAERP | CFO-2 | 602 | T+, C+ |
| cXi | PL- | CFO-1 | 908 | T+, C++ |
chA represents cyclohexyl-l-alanine, other abbrev. as per Fig. 1.
Fig. 1.(a) Schematic representation of the synthesis of FRET calpain substrates incorporating the CAL Fluor Orange 560 dye, C-extension represents either defined PEG d-Ala-Arg addition, and LinkerAM is an amide-producing linker frequently referred to as Rink linker. (b) Different spacer arm forms of the CAL Fluor Orange 560 dye.
Fig. 2.Intracellular fluorescence of cA following treatment of primary hippocampal neurons with ionomycin. In (a), hippocampal neurons (transmission image, left) were preloaded with cA (1 μM) for 30 min in a Ca2+-free experimental buffer and treatment with ionomycin (5 μM) followed by the addition of CaCl2 (0.2 mM) lead to the appearance of intracellular cA fluorescence (right). In (b), hippocampal neurons (transmission image, left) were exposed to CFO-GSG-free acid (10 μM), the predicted fluorescent calpain cleavage product of cA. Fluorescence remained extracellular and was excluded from cell bodies (right). Dark areas in B correspond to cell bodies while bright spots correspond to probe binding to cellular debris.
Fig. 3.Spectrofluorometric monitoring of calpain I-mediated cleavage of cA, cW and cX; buffer is 50 mM Tris–HCl at pH 7.5 containing 100 μM CaCl2, 1.5 mM DTT at 27 °C.
Fig. 4.Spectrofluorometric monitoring of calpain I and trypsin-mediated cleavage of cX or cW (conditions as per legend to Fig. 3).
Fig. 5.Spectrofluorometric monitoring of calpain I-, chymotrypsin- and trypsin-mediated cleavage of cX variants described in Table 2 (conditions as per legend to Fig. 3). (a) shows data from digests of cXa, (b) shows cXb, (c) shows cXc, (d) shows cXe, (e) shows cXf, (f) shows cXg, (g) shows cXi.
Fig. 6.Intracellular fluorescence of cXe following treatment of primary cortical neurons with ionomycin. Cortical neurons (transmission image, left) were preloaded with cXe (2 μM) for 40 min, washed to remove non-internalized cXe, then treated with ionomycin (5 μM). This resulted in increased intracellular fluorescence that was variable and accumulated in nuclei as cells underwent apoptotic rounding.